Role of ciprofloxacin in patients with cholestasis after endoscopic retrograde cholangiopancreatography

Table 1 Clinical characteristics of 48 patients undergoing ERCP

Characteristic	Ciprofloxacin(n = 22)		None-ciprofloxacin(n = 26)
	n	%	n	%
Sex (M:F)	13:9	59.1:40.9	11:15	42.3:57.7
Age (mean ± SD yr)	58.68 ± 13.7		61.08 ± 11.9
Causes
Bile duct stone	7	31.8	15	57.7
Cancer	13	59.1	11	42.3
Cholangiocarcinoma	6	27.3	6	23.1
Periampullary cancer	6	27.3	5	19.2
Hepatocellular cancer	1	4.5	0	0
Others	2	9.1	3	11.54
Bile duct stricture	1	4.5	1	3.8
Pseudocyst	1	4.5	0	0
Choledochal cyst	0	0	1	3.8
Chronicpancreatitis	0	0	1	3.8
Interventions
Stone extraction	5	22.7	13	50
Sphincterotomy	13	59.1	14	53.8
Stent placement	16	72.7	14	53.8

Table 2 Incidence of cholangitis and bacteremia in two study groups

Complication	Ciprofloxacin post-ERCP		Relative risk	95% CI
	Yes (n = 22)	No (n = 26)
Cholangitis	1 (4.5%)	2 (7.7%)	0.71	0.14-3.65
Bacteremia	13 (59.1%)	14 (53.8%)	1.12	0.60-2.11

Table 3 Bacterial species in cultures of bile from 48 patients

Bacterial culture	Antibiotic (22)n (%)	No antibiotic (26)n (%)	P
Negative	9 (40.9)	12 (46.2)	0.72
Positive	13 (59.1)	14 (53.8)	0.72
Gram negative
E. coli	4 (30.8)	3 (21.4)	0.81
Klebsella spp.	2 (15.4)	2 (14.3)	0.73
Pseudomonas spp.	2 (15.4)	1 (7.1)	0.88
Gram positive	3 (13.6)	9 (34.6)	0.09
Streptococcus viridans	3	4 (28.6)
Streptococcus bovis	0	1 (7.1)
Enterococcus fecalis	0	3 (21.4)
Staphylococcus spp.	0	1 (7.1)
Non C. albican	1 (7.7)	0

Table 4 Bile and hemoculture in three cholangitis patients

Group	Bacteriology
	Bile culture	Hemoculture
Antibiotic group	Streptococcus-viridans	Negative
No antibiotic group
First patient	E. coli	Negative
Second patient	Pseudomonas spp.	Negative